IMPORTANCE Cardiovascular adverse events (CVAE) with carfilzomib in patients with multiple myeloma can be potentially life-threatening and remain incompletely characterized. We performed the first systematic review and meta-analysis of carfilzomib-associated CVAE.
S urvival rates for patients with multiple myeloma (MM) have dramatically improved with the clinical development of proteasome inhibitors, thalidomide analogues, and monoclonal antibodies.
1 Cardiovascular adverse events (CVAE) are particularly important in MM given the overlapping risk factors for both MM and cardiovascular disease, such as older age and obesity, as well as a significant prevalence of coexisting cardiovascular disease in patients with MM.
2
In a study of over 30 000 patients with MM, nearly twothirds had cardiovascular disease at baseline and 70% developed cardiovascular events in a 6-year time period. 3 Thus, it is imperative to understand CVAE in this population, who are living longer with MM, have high rates of baseline cardiovascular disease, and are being exposed to an expanding portfolio of therapeutic agents with potential for cardiovascular toxic effects.
With patients with MM living longer, and with treatment options expanding, adverse event profiles are increasingly important in providing personalized care. A systematic review and meta-analysis of CVAE in patients receiving bortezomib, a first-in-class reversible proteasome inhibitor, showed a 3.8% rate of all-grade CVAE and a 2.3% rate of high-grade CVAE. An analysis of randomized studies did not find a significantly increased risk of CVAE in bortezomib arms compared with control arms. 4 Carfilzomib, the first irreversible proteasome inhibitor, is approved in the United States in combination with dexamethasone with or without lenalidomide for the treatment of patients with MM who have received at least 1 prior therapy based on the results of multiple clinical trials. [5] [6] [7] [8] Since its approval in 2012, there have been increasing reports of carfilzomib-associated CVAE, including heart failure, severe hypertension, cardiac arrhythmias, ischemic events, and cardiac arrest. [9] [10] [11] [12] Proposed mechanisms for these proteasome inhibitor-associated CVAE include oxidative stress on cardiac myocytes, endothelial effects as a result of proteasome inhibition leading to hypertension and vascular dysfunction, and an increase in coronary vascular tone and reactivity. [13] [14] [15] [16] Further underlying the importance of endothelial dysfunction in cardiorenal dysfunction, direct endothelial toxic effects have been suggested to underlie the mechanism of carfilzomibassociated acute kidney injury and thrombotic microangiopathy as well.
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The nature and incidence of carfilzomib-associated CVAE is not currently known. Clinical trials performed in different patient populations and with varying treatment parameters (eg, dose, infusion duration, combination regimens) have shown varying rates of CVAE. We have to our knowledge performed the first systematic review and meta-analysis to specifically address carfilzomib-associated CVAE to determine the rate of CVAE and to explore potential reasons for varying CVAE rates reported among trials.
Methods

Search Methods and Study Selection
This systematic review and meta-analysis was performed in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. 18, 19 We performed a systematic review of studies cited in Medline (via PubMed) from January 1, 2007, to January 1, 2017, using the search terms "carfilzomib," "Kyprolis", and "PX-171." Because the purpose of this study was to summarize the incidence of overall and high-grade CVAE in patients with MM receiving carfilzomib, we restricted our study to prospective clinical trials in which adult, human participants received carfilzomib for MM. To allow for comparability between trials, only studies in which adverse events were reported using the Common Terminology Criteria for Adverse Events (CTCAE) version 3 or 4 in the English language were included. To avoid additional selection or ascertainment bias, studies in which toxic effects data were collected retrospectively and substudies of separately reported prospective trials were excluded from analysis. Preclinical studies and studies with nonhuman subjects were excluded. The EMBASE and Web of Science databases were also queried with the same search terms to identify additional studies. All studies were selected and reviewed by 2 independent reviewers (A.J.W. and S.C.).
Data Extraction
Data were extracted for all studies reporting nonhematologic toxic effects associated with carfilzomib. The primary outcome was an aggregate outcome of overall CVAE rates including heart failure, hypertension, cardiac ischemia, arrhythmia, and cardiac arrest. Outcomes of heart failure, hypertension, cardiac ischemia, arrhythmia, and cardiac arrest were treated as secondary outcomes. All-grade and highgrade (grade ≥3) treatment-emergent CVAE were abstracted on the basis of sets of CTCAE definitions (eTable in the Supplement). These outcomes were abstracted for each eligible study, counting participants documented as having multiple CVAE once when that information was available. In addition, CT-CAE outcomes of dyspnea and edema were abstracted but not included in the aggregate endpoint owing to the possibility that these could represent a mixture of pulmonary and cardiovascular adverse events. Study-level characteristics were abstracted ( Meaning Carfilzomib is associated with a high rate of clinically significant CVAEs, which underscores a need for increased awareness of these adverse events and further study into optimal patient selection and risk mitigation strategies.
in control groups that did not receive carfilzomib were also abstracted. Data were collected using a standardized data collection instrument by both reviewers. Results were reconciled during a consensus meeting. When consensus could not be reached, a third reviewer (B.M.W.) was consulted to resolve discrepancies. Preconsensus inter-rater reliability was assessed using both absolute inter-rater agreement and the κ statistic.
Meta-analysis
The rates of CVAE in each study were calculated by dividing the number of each CVAE by the total sample size. Binomial exact 95% confidence intervals (CIs) were calculated. 20 To avoid inducing bias toward a higher event rate from employing a fixed continuity correction for studies witha0eventrate, data were transformed using the Freeman-Tukey Double Arcsine transformation without continuity correction. The transformed CVAE rates were pooled using a random effects model as described by DerSimonian and Laird. 21 A random effects model was selected a priori owing to expected treatmenteffect heterogeneity from differences in study designs. Heterogeneity was quantified using the τ 2 and I 2 statistics. Prespecified subgroup analyses were performed using study characteristic stratification and differences were assessed using the Q-test, which tests the null hypothesis that there is no between-group heterogeneity. For the randomized clinical trials, relative risk (RR) of CVAE were calculated by dividing the CVAE rate in the experimental carfilzomib group by the CVAE rate in the control group. These individual study RRs were pooled using the Peto method to compute a summary RR.
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Publication bias was assessed by querying a national clinical trials registry (clinicaltrials.gov) for unreported completed or discontinued trials and by review of abstracts presented at national meetings. Publication bias and small study effects were also assessed graphically via funnel plot and mathematically using Begg's rank correlation test. 23 All statistical analyses were performed using STATA statistical software (version 14.2, StataCorp).
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Results
Eligible Studies and Characteristics
Our initial literature search revealed 524 potential studies for review ( Figure 1 ). Following exclusion of review articles, preclinical and animal studies, case reports and case series, clinical guidelines and editorials, studies without toxic effects data, retrospective analyses and studies for alternate indications, we identified 24 prospective studies of patients receiving carfilzomib for MM. [5] [6] [7] A total of 2594 patients with MM were included. Interrater agreement for study inclusion was 99.2% (κ = .92, P < .001). The 24 included studies included a range of trial sizes (7-513 patients receiving carfilzomib), phases, number of prior myeloma therapies, maximum doses of carfilzomib administered (15 mg/m 2 to 88 mg/m 2 ), and companion therapy. High-grade CVAE data was available for all 24 included studies whereas all-grade CVAE data was available in 22 studies. All studies excluded patients with amyloidosis and had at least some exclusion criteria on the basis of cardiac function or comorbidities. Summary study and patient level characteristics are listed in Table 1 .
RatesofCVAE
The rate of all-grade CVAE ranged from 0% to 52% and the rate of high-grade CVAE ranged from 0% to 45%. Interrater agreement for CVAE was 95.6%. On pooling the data using the random effects model (Figure 2A and B) , summary all-grade and high-grade CVAE rates were 18.1% and 8.2%, respectively. Both estimates showed substantial heterogeneity as quantified by I 2 statistics of 87.4% and 71.6% for all-grade and high-grade CVAE, respectively, which represent the fraction of variability in studies not attributable solely to sample size. Heart failure (4.1%) and hypertension (12.2%) were the most common types of CVAE, whereas arrhythmias (2.4%) and ischemic events (1.8%) were comparatively less common ( Table 2) . Of 2594 patients, there were 6 reported carfilzomib-associated cardiac arrests. This was not significantly different from 0 (P > .99). Reports of all-grade dyspnea (23.9%) and edema (24.7%) were relatively common, but information on the underlying causes of these adverse events were limited. 
Subgroup Analysis
Heterogeneity was explored using subgroup analysis on the basis of study-level patient-and therapy-associated characteristics ( Table 3) . We found that the phase of trial and dose of carfilzomib were both significantly associated with higher rates of high-grade CVAE, with phase 1 trials having a rate of 2.3% compared with 9.5% for phase 2 and 3 trials (P = .02) and doses of carfilzomib smaller than 45 mg/m 2 ha vin gara teof6 .4 % compared with 11.9% for doses of 45 mg/m 2 or more (P = .02).
Median age of study participants, whether MM was newly diagnosed or relapsed/refractory, number of prior therapies, and duration of carfilzomib exposure were not associated with differing rates of CVAE or reduced heterogeneity. Longer infusion duration (30 minutes vs ≤10 minutes) demonstrated a trend toward higher rates of high-grade CVAE (11.0% vs 6.7%, P = .06). However, studies with a 30-minute infusion length were far more likely to have a higher dose of carfilzomib (OR, 8.6; 95% CI, 1.4-51.7; P = .02).
Relative Rates of CVAE in Randomized Clinical Trials
To assess the relative rate of carfilzomib CVAE compared with CVAE in otherwise identical control arms, we calculated the relative risk of developing CVAE in the 3 randomized clinical trials in which carfilzomib was administered in the experimental arm and computed a summary relative risk estimate ( Figure 2C ). The following trials in patients with relapsed MM were included: ASPIRE (carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone), EN-DEAVOR (carfilzomib and dexamethasone vs bortezomib and dexamethasone), and FOCUS (carfilzomib and dexamethasone vs dexamethasone with or without cyclophosphamide).
5-7
All 3 trials were of high quality and followed CONSORT 2010 guidelines. For high-grade CVAE, receipt of carfilzomib was associated with a greater than 2-fold increase in risk (summary relative risk, 2.2; 95% CI, 1.6-2.9; P < .001; I 2 = 0%). Results for all-grade CVAE were similar, with a summary relative risk of 1.8 (95% CI, 1.4-2.2; P < .001, I 2 = 14.8%). A sensitivity analysis was performed excluding hypertension to assess whether these findings were driven by hypertension. Excluding hypertension yielded similar results; the summary relative risk was 2.6 (95% CI, 1.4-4.6; P = .002) for high-grade events and 1.9 (95% CI, 1.1-3.3; P = .02) for all-grade events.
Publication Bias Assessment
Studies were assessed for publication bias and small-study effects. Review of clinicaltrials.gov did not reveal additional completed studies with results that were not found in the published literature. Visual inspection of funnel plots (eFigure in the Supplement) and Begg's test revealed asymmetry with a moderate correlation between greater sample size and more high-grade CVAE (P = .03). Significant asymmetry was not found for all-grade CVAE (P = .07).
Discussion
To our knowledge, this is the first systematic review and metaanalysis specifically assessing carfilzomib-associated CVAE. We note 4 key findings. First, from 24 studies including 2594 patients, we determined robust estimates of the rates of allgrade and high-grade CVAE with carfilzomib of 18.1% and 8.2%, respectively. Second, higher doses of carfilzomib were associated with higher rates of CVAE whereas infusion rate was not associated with different rates of CVAE. Third, rates of CVAE differ according to trial phase, suggesting a possible systematic underdetection or underreporting in early phase studies. Finally, we found that carfilzomib was associated with an elevated risk of high-grade and all-grade CVAE compared with noncarfilzomib control groups. Taken together, these findings indicate that carfilzomib confers an elevated risk of CVAE. These findings are largely consistent with those recently discussed in an extensive review of safety issues of new treatments for multiple myeloma by Brioli et al. 46 These include higher rates of CVAE noted in carfilzomib arms and greater CVAE rates in studies in which patients received higher doses of carfilzomib. Our study provides a rigorous, systematic, and quantitative analysis that meaningfully adds to the literature by confirming, quantifying, and statistically assessing these effects as well as exploring other important differences between trials on the rates of CVAE in patients receiving carfilzomib.
The pathogenesis of CVAE in the population of patients receiving proteasome inhibitors is not currently well understood. A prenatal mouse model has shown that exposure to proteasome inhibitors can induce oxidative stress leading to myocardial dysfunction, particularly in conjunction with anthracyclines.
14 Further support for proteasome inhibitorinduced oxidative stress has been shown by Imam et al, 13, 47 who demonstrated that apremilast, an inhibitor of phosphdiesterase 4, reduces oxidative stress and carfilzomib cardiotoxic effects in a rat model. Other studies have shown that echocardiographic findings are not necessarily indicative or predictive of CVAE, raising the concern for endothelial effects as a potential mechanism. 15, 48 Carfilzomib is also known to cause renal toxic effects and microangiopathy that is also believed to be mediated by endothelial dysfunction. 15, 17, 49 An in-vitro study showed increased coronary vascular tone and decreased coronary relaxation in response to nitroglycerin in hearts exposed to carfilzomib. 16 Taken together, these studies reveal a complex mechanism of proteasome inhibitorassociated CVAE that involves changes to both the myocardium and vasculature that may be more severe with carfilzomib than bortezomib owing to the irreversible nature of proteasome inhibition with carfilzomib. Our study found a lower rate of CVAE in early phase compared with later phase studies. In addition, we found that smaller study size correlated with fewer CVAE. One possible explanation for this would be nonpublication of small studies showing high rates of CVAE. However, our review of trial registries did not demonstrate nonpublication of small studies, which would be unlikely given that CVAE are not the primary endpoint of any of these studies. Rather, this relationship may be owing to systematic underdetection or underreporting of CVAE in smaller and earlier phase studies or exclusion of patients at elevated risk for CVAE from phase 1 studies. Furthermore, limitations in reporting of low-grade and longitudinal toxic effects has been described in the setting of limited follow-up at the time of publication. 50 In either case, this may indicate that our summary effect size may underestimate the true mean rate of carfilzomib-associated CVAE in the general population. We included hypertension in our aggregate endpoint of CVAE. Treatment-emergent hypertension is clinically significant because hypertension often precedes left ventricular diastolic and systolic dysfunction.
9,51 Mechanistically, the association between carfilzomib use and hypertension is important given previously reported endothelial effects of proteasome inhibitors. 15, 17, 49 The relationship between hypertension leading to diastolic dysfunction and clinical heart failure may explain the finding of low rates of reduced ejection fraction by echocardiography in a substudy of ENDEAVOR despite elevated rates of clinical heart failure in the carfilzomib arm because heart failure with preserved ejection fraction may account for many observed events. 48 Although a considerable proportion of all-grade CVAE in our meta-analysis could be attributed to hypertension, our finding of greater rates of CVAE in participants receiving carfilzomib compared with controls is consistent whether hypertension is included in the aggregate outcome or not. This suggests a need for further study to explore methods of monitoring and treating hypertension among patients receiving carfilzomib.
Limitations
There are several limitations to the present study. Because this is a study-level analysis, it is not possible to make inferences regarding which individual patients are at higher risk of CVAE. Because subgroup analysis is powered on the basis of number of studies rather than total number of patients, we were only able to assess 1 characteristic at a time, precluding a multivariate analysis to assess multiple potential factors simultaneously. Ascertainment of CVAE may be limited by variable reporting between studies because it is possible to have different grades for the same event dependent on the adjudicator. For example, an asymptomatic reduction in ejection fraction may be ascertained as either a grade 1 heart failure event or a grade 3 decline in ejection fraction. 52 Moreover, some events adjudicated as dyspnea or edema may represent underlying CVAE that were not diagnosed owing to lack of ejection fraction monitoring, leading to underestimation. 52 Other events that may be clinically important but are uncommon, such as treatmentemergent pulmonary hypertension, are not well represented in the data. In addition, all studies included explicit and often broad exclusion criteria on the basis of cardiovascular history and function, limiting the generalizability of our results to patients with cardiac comorbidities, which accounts for a significant proportion of real-world patients with MM receiving carfilzomib. Prior studies have suggested that patients with MM have elevated rates of CVAE compared with the general population. 2, 30 This finding may be related to the overlap between cardiovascular disease risk factors and the population of patients with MM, including older age and obesity, as well as disease-related factors, such as anemia and renal dysfunction.
2 Our study demonstrates a rate of high-grade CVAE approximately twice as high among patients receiving carfilzomib compared with noncarfilzomib-receiving controls. This is of particular importance given that the MM patient population is at an elevated baseline risk of CVAE, underscoring the importance of delineating the cardiovascular risk of therapies for MM.
Conclusions
Our systematic review and meta-analysis demonstrates an 8.2% rate of high-grade carfilzomib CVAE and 18.1% risk of carfilzomib CVAE with higher doses of carfilzomib associated with more CVAE. It is critical that clinicians caring for patients with MM be aware of early signs of CVAE and promptly refer such patients for additional evaluation and to hold carfilzomib. Further study is needed to assess patient-level risk factors to predict which patients are at highest risk of developing carfilzomib CVAE as well as to establish optimal monitoring strategies for patients receiving carfilzomib and to develop strategies to mitigate this risk, including determining which patients may be able to safely restart the drug at a reduced dose.
